Skip to main content
. 2018 Jun 21;24(23):2457–2467. doi: 10.3748/wjg.v24.i23.2457

Figure 2.

Figure 2

Real-world studies with vedolizumab in patients with ulcerative colitis (A) and Crohn’s disease (B): Results at week 14.

HHS Vulnerability Disclosure